Samsung Biologics Scores Another 'Big Deal' in Europe... Annual Cumulative Orders Surpass 5 Trillion Won

Two New Contracts Worth a Total of 930 Billion KRW with European Pharmaceutical Companies
Over 1 Trillion KRW Big Deals, 3 Deals This Year Alone... First Ever Since Establishment

Samsung Biologics has surpassed a cumulative annual order amount of 5 trillion KRW for the first time since its establishment by signing consecutive 'big deals' with global pharmaceutical companies.

A view of Samsung Biologics Plant 4 located in Songdo, Incheon. Provided by Samsung Biologics

On the 20th, Samsung Biologics announced through a public disclosure that it had signed a contract worth 930.4 billion KRW (668.39 million USD) for contract manufacturing (CMO) with a European pharmaceutical company. This contract consists of two deals worth 752.4 billion KRW and 178 billion KRW respectively, and the total order amount accounts for about 30% of the entire order amount of the previous year (3.5009 trillion KRW). The client and product names have not been disclosed due to confidentiality agreements, and the contract period lasts until December 31, 2031.

Starting with the first contract in March this year, Samsung Biologics has signed a total of 11 orders with global pharmaceutical companies based on public disclosures, achieving 5.3 trillion KRW in orders in 11 months, which is 1.5 times the order amount of the previous year. In particular, this year alone, it has secured large-scale orders by consecutively signing mega contracts across the globe including the United States, Asia, and Europe, proving its world-class contract development and manufacturing organization (CDMO) capabilities.

In July, it began with a contract worth 1.46 trillion KRW with a U.S. pharmaceutical company, and in October, it signed a contract worth 1.7 trillion KRW with an Asian pharmaceutical company, breaking its record for the largest order amount in just over three months. Including this contract, there have been three big deals worth over 1 trillion KRW each this year.

Samsung Biologics currently has 17 out of the top 20 global pharmaceutical companies as clients. Based on overwhelming production capacity, quality competitiveness, and numerous track records, the cumulative total order amount since its founding has exceeded 16.1 billion USD.

To proactively prepare for the increasing demand for biopharmaceuticals, it is also expanding its production capacity. The 5th plant, with a capacity of 180,000 liters that consolidates the best practices of plants 1 through 4, is under construction with the goal of starting operations in April 2025. Upon completion, Samsung Biologics will secure a total production capacity of 784,000 liters.

In terms of quality, it has demonstrated excellent quality competitiveness throughout the entire pharmaceutical manufacturing and management process, achieving a 99% batch success rate. Additionally, as of the end of October, it has obtained a total of 339 manufacturing approvals from global regulatory agencies in its 13 years since establishment, including 38 from the U.S. Food and Drug Administration (FDA) and 33 from the European Medicines Agency (EMA).